Focused radiation boost for intermediate and high-risk prostate cancer
This trial tests whether adding an extra, targeted dose of radiation to the main tumor during standard radiation therapy can better control prostate cancer. It is for patients with intermediate or high-risk prostate cancer that has not spread, and who are eligible for a shorter course of radiation (20 sessions).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of prostate cancer (adenocarcinoma).
- Your cancer must be classified as intermediate or high-risk (based on standard criteria).
- Your cancer must not have spread to lymph nodes or other parts of the body.
- You must be in good physical condition (able to care for yourself, up and about).
- You must have at least one suspicious area seen on an MRI (called PI-RADS 4 or 5), or a PI-RADS 3 area that is confirmed as cancer by biopsy.
- You must be able to understand Italian and follow study instructions.
- You must not have had previous prostate treatments like radiation, brachytherapy, cryosurgery, or HIFU.
- You must not have had radiation to the pelvic area before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
This trial tests whether giving an extra, focused dose of radiation to the visible tumor inside the prostate can improve results for men with intermediate or high-risk prostate cancer that has not spread. The total treatment is given in 12 or 20 sessions.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
Hear when a new Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.